Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis
暂无分享,去创建一个
[1] O. Abdel-Rahman,et al. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. , 2014, Critical reviews in oncology/hematology.
[2] O. Abdel-Rahman,et al. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis , 2014, Expert review of anticancer therapy.
[3] M. Shaker,et al. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. , 2014, Journal of the Egyptian National Cancer Institute.
[4] Ying Cheng,et al. Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines , 2014, Cancer Cell International.
[5] O. Abdel-Rahman. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. , 2013, Journal of the Egyptian National Cancer Institute.
[6] Sung-Bae Kim,et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. , 2013, European journal of cancer.
[7] S. Paik,et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.
[8] M. Rubin,et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] O. Abdel-Rahman,et al. Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature , 2013, Digestive Diseases and Sciences.
[10] H. Gómez,et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Lacouture,et al. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. , 2013, Journal of the American Academy of Dermatology.
[12] R. Shah,et al. Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives , 2013, Drug Safety.
[13] D. Hicks,et al. The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma , 2013, Biotechnic & histochemistry : official publication of the Biological Stain Commission.
[14] H. Gómez,et al. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer , 2013, Breast Cancer Research and Treatment.
[15] H. Gómez,et al. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer , 2012, Breast Cancer Research and Treatment.
[16] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[17] M. Shaker,et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma , 2012, Medical Oncology.
[18] A. Musolino,et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Gelber,et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial , 2012, The Lancet.
[20] M. Rezai,et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. , 2012, The Lancet. Oncology.
[21] A. Luini,et al. Lapatinib Activity in Premalignant Lesions and HER-2–Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial , 2011, Cancer Prevention Research.
[22] K. King,et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] B. Monk,et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Untch,et al. Lapatinib – Member of a New Generation of ErbB-Targeting Drugs , 2010, Breast Care.
[25] H. Gómez,et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Betsy Paul,et al. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[27] Frank Pétavy,et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[29] M. Berger,et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.
[30] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[31] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[32] W. Gradishar,et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.
[33] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[34] 下山正徳. National Cancer Institute-Common Toxicity Criteria , 1999 .